Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers

被引：3
作者：
Zaaijer, Leendert H. [1 ,2 ]
van Doorn, Helena C. [1 ]
Mourits, Marian J. E. [3 ]
van Beurden, Marc [4 ]
de Hullu, Joanne A. [5 ]
Adank, Muriel A. [6 ]
van Lonkhuijzen, Luc R. C. W. [7 ]
Vasen, Hans F. A. [8 ]
Slangen, Brigitte F. M. [9 ]
Gaarenstroom, Katja N. [10 ]
Zweemer, Ronald P. [11 ]
Vencken, Peggy M. L. H. [12 ]
Seynaeve, Caroline [2 ]
Kriege, Mieke [2 ]
机构：
[1] Erasmus MC Canc Inst, Dept Obstet & Gynaecol, Rotterdam, Netherlands
[2] Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Obstet & Gynaecol, Groningen, Netherlands
[4] Netherlands Canc Inst NKI AVL, Dept Obstet & Gynaecol, Amsterdam, Netherlands
[5] Radboud Univ Nijmegen, Med Ctr, Dept Obstet & Gynaecol, Nijmegen, Netherlands
[6] Vrije Univ Amsterdam Med Ctr, Dept Clin Genet, Amsterdam, Netherlands
[7] Acad Med Ctr, Ctr Gynecol Oncol, Amsterdam, Netherlands
[8] Fdn Detect Hereditary Tumours STOET, Leiden, Netherlands
[9] Maastricht Univ, Dept Obstet & Gynaecol, Med Ctr, Maastricht, Netherlands
[10] Leiden Univ, Dept Obstet & Gynaecol, Med Ctr, Leiden, Netherlands
[11] UMC Utrecht, Dept Gynaecol Oncol, Ctr Canc, Utrecht, Netherlands
[12] Bravis Hosp, Dept Obstet & Gynaecol, Bergen Op Zoom, Norway
来源：
BRITISH JOURNAL OF CANCER | 2016年 / 115卷 / 10期
关键词：
BRCA mutation; breast cancer; ovarian cancer; survival; chemotherapy; WOMEN;
D O I：
10.1038/bjc.2016.333
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: It is unknown whether a history of breast cancer (BC) affects the outcome of BRCA1/2-associated epithelial ovarian cancer (EOC). This was investigated in the current analysis. Methods: We included 386 BRCA1/2-associated EOC patients diagnosed between 1980 and 2015. Progression-free survival (PFS), progression-free interval (PFI), overall survival (OS) and ovarian cancer-specific survival (OCSS) were compared between EOC patients with and without previous BC. Results: BRCA-associated EOC patients with, vs without, a BC history had a significantly worse PFS and PFI (multivariate hazard ratio (HRmult) 1.47; 95% confidence interval (CI) 1.03-2.08 and HRmult 1.43; 95% CI 1.01-2.03), and a non-significantly worse OS (HRmult 1.15; 95% CI 0.84-1.57) and OCSS (HRmult 1.18; 95% CI 0.85-1.62). Ovarian cancer-specific survival was significantly worse for the subgroup treated with adjuvant chemotherapy for BC (HRmult 1.99; 95% CI 1.21-3.31). Conclusions: Our results suggest that BRCA1/2-associated EOC patients with a previous BC have a worse outcome than EOC patients without BC, especially when treated with adjuvant chemotherapy.
引用
收藏
页码：1174 / 1178
页数：5
相关论文
共 9 条
[1]   BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group [J].
Alsop, Kathryn ;
Fereday, Sian ;
Meldrum, Cliff ;
deFazio, Anna ;
Emmanuel, Catherine ;
George, Joshy ;
Dobrovic, Alexander ;
Birrer, Michael J. ;
Webb, Penelope M. ;
Stewart, Colin ;
Friedlander, Michael ;
Fox, Stephen ;
Bowtell, David ;
Mitchell, Gillian .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) :2654-2663
[2]   Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation [J].
Finch, Amy P. M. ;
Lubinski, Jan ;
Moller, Pal ;
Singer, Christian F. ;
Karlan, Beth ;
Senter, Leigha ;
Rosen, Barry ;
Maehle, Lovise ;
Ghadirian, Parviz ;
Cybulski, Cezary ;
Huzarski, Tomasz ;
Eisen, Andrea ;
Foulkes, William D. ;
Kim-Sing, Charmaine ;
Ainsworth, Peter ;
Tung, Nadine ;
Lynch, Henry T. ;
Neuhausen, Susan ;
Metcalfe, Kelly A. ;
Thompson, Islay ;
Murphy, Joan ;
Sun, Ping ;
Narod, Steven A. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15) :1547-U43
[3]   Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer [J].
Hyman, David M. ;
Zhou, Qin ;
Iasonos, Alexia ;
Grisham, Rachel N. ;
Arnold, Angela G. ;
Phillips, Mary F. ;
Bhatia, Jasmine ;
Levine, Douglas A. ;
Aghajanian, Carol ;
Offit, Kenneth ;
Barakat, Richard R. ;
Spriggs, David R. ;
Kauff, Noah D. .
CANCER, 2012, 118 (15) :3703-3709
[4]   The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers [J].
Metcalfe, KA ;
Lynch, HT ;
Ghadirian, P ;
Tung, N ;
Olivotto, IA ;
Foulkes, WD ;
Warner, E ;
Olopade, O ;
Eisen, A ;
Weber, B ;
McLennan, J ;
Sun, P ;
Narod, SA .
GYNECOLOGIC ONCOLOGY, 2005, 96 (01) :222-226
[5]   Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer [J].
Risch, HA ;
McLaughlin, JR ;
Cole, DEC ;
Rosen, B ;
Bradley, L ;
Kwan, E ;
Jack, E ;
Vesprini, DJ ;
Kuperstein, G ;
Abrahamson, JLA ;
Fan, I ;
Wong, B ;
Narod, SA .
AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 68 (03) :700-710
[6]  
Thompson D, 2002, JNCI-J NATL CANCER I, V94, P1358, DOI 10.1093/jnci/94.18.1358
[7]   Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands [J].
Vencken, P. M. L. H. ;
Reitsma, W. ;
Kriege, M. ;
Mourits, M. J. E. ;
de Bock, G. H. ;
de Hullu, J. A. ;
van Altena, A. M. ;
Gaarenstroom, K. N. ;
Vasen, H. F. A. ;
Adank, M. A. ;
Schmidt, M. K. ;
van Beurden, M. ;
Zweemer, R. P. ;
Rijcken, F. ;
Slangen, B. F. M. ;
Burger, C. W. ;
Seynaeve, C. .
ANNALS OF ONCOLOGY, 2013, 24 (08) :2036-2042
[8]   Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients [J].
Vencken, P. M. L. H. ;
Kriege, M. ;
Hoogwerf, D. ;
Beugelink, S. ;
van der Burg, M. E. L. ;
Hooning, M. J. ;
Berns, E. M. ;
Jager, A. ;
Collee, M. ;
Burger, C. W. ;
Seynaeve, C. .
ANNALS OF ONCOLOGY, 2011, 22 (06) :1346-1352
[9]   Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer [J].
Yang, Da ;
Khan, Sofia ;
Sun, Yan ;
Hess, Kenneth ;
Shmulevich, Ilya ;
Sood, Anil K. ;
Zhang, Wei .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (14) :1557-1565
1